Since being forced into court receivership March 8, Korean ultrasound developer Medison had been seeking a white knight. But no more. The company best known for its pioneering efforts in 4D ultrasound has decided to stop looking for a corporate savior
Since being forced into court receivership March 8, Korean ultrasound developer Medison had been seeking a white knight. But no more. The company best known for its pioneering efforts in 4D ultrasound has decided to stop looking for a corporate savior and make it on its own. The company had attracted several suitors, including a number of foreign and domestic firms and a consortium. In each case, however, the proposed terms were too severe for Medison executives to accept, according to the company. In the meantime, the firm has divested itself of activities outside medical ultrasound and has posted strong sales revenue during this year's first half, leading to optimism that the company can succeed by itself.
Study Reaffirms Low Risk for csPCa with Biopsy Omission After Negative Prostate MRI
December 19th 2024In a new study involving nearly 600 biopsy-naïve men, researchers found that only 4 percent of those with negative prostate MRI had clinically significant prostate cancer after three years of active monitoring.
Study Examines Impact of Deep Learning on Fast MRI Protocols for Knee Pain
December 17th 2024Ten-minute and five-minute knee MRI exams with compressed sequences facilitated by deep learning offered nearly equivalent sensitivity and specificity as an 18-minute conventional MRI knee exam, according to research presented recently at the RSNA conference.
Can Radiomics Bolster Low-Dose CT Prognostic Assessment for High-Risk Lung Adenocarcinoma?
December 16th 2024A CT-based radiomic model offered over 10 percent higher specificity and positive predictive value for high-risk lung adenocarcinoma in comparison to a radiographic model, according to external validation testing in a recent study.